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The benzidine dye initiative is a research program established by the National Toxicology Program to generate an integrated body of scientific
information regarding the potential health risks associated with exposure to benzidine- and benzidine-congener-derived dyes. Because an in-
depth evaluation of each of the hundreds of benzidine-congener-derived dyes was considered impractical, the research program was de-
signed to study the metabolism and disposition, genetic toxicity, and in vivo toxicity and carcinogenicity of two primary benzidine congeners,
3,3'-dimethylbenzidine and 3,3'-dimethoxybenzidine, and a select group of prototypical dyes derived from those amines. It was anticipated
that by applying the basic information generated in these extensive studies, it would be possible to make regulatory decisions about other
dyes after conducting only a minimal number of experiments such as studies of disposition and metabolism, and in vitro mutagenicity. This
paper summarizes the results of studies conducted to evaluate the metabolism, disposition, mutagenicity, toxicity, and carcinogenicity of rep-
resentative benzidine congeners and derived dyes. - Environ Health Perspect 102(Suppl 2):63-78 (1994).
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Introduction
Haley (1) reviewed the early literature on
the toxicologic and carcinogenic effects of
benzidine and a new review is currently in
progress by the Agency for Toxic
Substances and Disease Registry. Since the
intent of our communication is to present
a body ofexperimental results, only a brief
review of clinical and experimental high-
lights will be presented.
An increased incidence of cancer of the
urinary bladder was first associated with
human occupational exposure to dyes and
dye chemicals in 1895 (1). These tumors,
initially referred to as aniline cancers be-
cause of the extensive use of aniline in dye
chemistry, were attributed to exposure to ei-
ther the starting materials or to the finished
dyes per se. Over the intervening years sev-
eral aromatic amines, used as starting mate-
rials in the dye manufacturing process, were
shown to be animal carcinogens and benzi-
dine was identified as a carcinogen for the
human urinary bladder in 1973 (1).
Simultaneously the results of cancer epi-
demiology studies in Japanese Kimono
painters implicated benzidine-derived dyes
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as human carcinogens. In addition, two
congeners of benzidine, 3,3'-dimethylben-
zidine and 3,3'-dimethoxybenzidine, also
employed in the dye industry, were found
to increase tumor incidence in rats (1).
The results ofthese early studies on 3,3'-di-
methylbenzidine and 3,3'-dimethoxybenzi-
dine were difficult to interpret because of
the small groups of animals used and re-
duced survival.
Although certain benzidine-derived dyes
(e.g., Direct Blue 6, Direct Brown 95, and
Direct Black 38) were considered to be car-
cinogenic in rats (2), it remained to be estab-
lished whether the carcinogenic action was
attributable to the dyes per se, trace levels of
benzidine present in the dyes as a contami-
nant, or metabolites ofthe dyes. Further, in
addition to equivocal data concerning the
carcinogenicity of 3,3'-dimethylbenzidine
and 3,3'-dimethoxybenzidine, dyes derived
from either of these benzidine congeners
had not been adequately studied for car-
cinogenic activity.
These questions concerning possible
carcinogenicity, combined with the poten-
tial for exposure of humans to the benzi-
dine congeners during dye manufacture
and to the dyes during their use, prompted
the design and conduct ofa series ofexper-
iments to explore the carcinogenic poten-
tial of several benzidine-congener-derived
dyes in rats. The US Environmental
Protection Agency, the Consumer Pro-
tection and Safety Commission, and the
Occupational Safety and Health Agency
nominated several benzidine dyes for car-
cinogenicity testing by the National
Toxicology Program (NTP). During the
planning stages it was recognized that a
large number of dyes existed and that
should one or more be found to possess
undesirable biological activity an alternate,
most likely ofill defined toxicologic poten-
tial, would be readily available as a substi-
tute. The substitute would then require
testing before regulatory decisions relative
to its use could be made. Such a circuitous
path would have placed an enormous bur-
den on the resources ofthe NTP.
To circumvent this potential dilemma
the collaborating agencies agreed to imple-
ment a research program on the benzidine
congeners and dyes derived from them, the
results of which could be used to predict
the carcinogenic potential of other benzi-
dine-congener-derived dyes. The broad ob-
jective of the initiative was to generate an
integrated body of scientific information
regarding the potential health risks likely to
be associated with exposure to any benzi-
dine-congener-derived dye. To this end,
experiments were designed to study the
metabolism and disposition, genetic toxic-
ity, and in vivo toxicity and carcinogenicity
of 3,3'-dimethylbenzidine and 3,3'-
dimethoxybenzidine, and a select group of
prototypical dyes derived from those
amines. It was anticipated that by applying
the basic information generated in these ex-
Environmental Health Perspectives 63MORGANETAL.
tensive studies it would be possible to make
regulatory decisions about other dyes after
conducting only a minimal number of ex-
periments such as studies of disposition
and metabolism, and in vitro mutagenicity.
Chemistry
Nomendature andStructure
Nomenclature of colorants can be confus-
ing. The difference between dyes and pig-
ments is in the method used to apply the
coloring agent. Dyes are applied as a solu-
tion or a vapor while pigments are applied
without losing their crystalline structure.
The Colour Index (C.I.) (3) names dyes by
reference to application class and shade,
and by using a sequential number. The
dyes used in the current studies belong to
the direct and acid application classes
which are water-soluble anionic dyes (4).
Benzidine- and benzidine-congener- (i.e.,
chemically related to benzidine) based dyes
include those derived from 3,3'-dimethyl-
benzidine and 3,3'-dimethoxybenzidine, as
well as benzidine itself. Synonyms for 3,3'-
dimethylbenzidine and 3,3'-dimethoxyben-
zidine, the benzidine congeners used in the
studies reported here, are o-toluidine and o-
dianisidine, respectively. Chemical struc-
tures, CAS numbers, and C.I. numbers for
benzidine, the benzidine congeners, and
the related dyes that were studied are pre-
sented in Table 1.
Synthesis
Benzidine and its congeners are dye inter-
mediates, i.e., precursors of dyes. A com-
mon method used to prepare benzidine
and congeners involves the reduction ofni-
trobenzenes followed by the acid catalyzed
intramolecular rearrangement ofthe result-
ing hydrazobenzenes. Subsequently, the
dyes are produced by the diazotization of
the amino groups on the benzidines and
azo coupling to reactive aromatic ring sys-
tems (other dye intermediates). A general-
ized synthetic scheme is shown in Figure 1.
Metallizing of dyes sometimes is carried
out to improve the stability of the azo
groups; however, the mechanism by which
the added metal chelates with the dye is
not always well understood. For the one
metallized dye used in our carcinogenesis
studies, C.I. Direct Blue 218, the structure
has not been completely defined. However,
the synthetic route consists of coupling 1
mole ofo-dianisidine (3,3'-dimethoxybenz-
idine) to 2 moles of 4-amino-5-hydroxy-
2,7-napthalene disulfonic acid under
alkaline pH conditions followed by metal-
lizing and elimination of methyl groups
Table 1. Benzidine-based dyes studied in the National Toxicology Program Initiative.
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Table 1. Continued.
Chemicals Tests Structure
33'-Dlhydroxyboldlem derived
C.l. Direct Blue 218 S. C
CAS #10401-50-0
Cl #24401
3 3'-Dlmethoxybsnzldlmn derived
3,3'-Dirmethoxybenzidine-2HCI S. M, C
CAS #20325-40-0
C.I. Direct Blue 15
CAS #2429-74-5
Cl #24400
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Cl #24140
C.I. Direct Blue 1
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Cl #24340
C.l. Direct Violet 32
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S =Salmonella mutagenicitytesting. M= metabolism studies. C =toxicology andcarcinogenesis studies. CI# = Color
Index Number. CAS# =chemical abstract number.
from the methoxides to form the copper
complex (5). Depending on the synthesis
methods employed and the needs of the
end user, the dyes may be impure "press-
cakes" or highly pure crystalline products.
The most important property of the dyes
to the end user is the color, while purity is
ofsecondary concern. Because humans are
exposed to these impure commercial prod-
ucts, commercial sources for the test mate-
rials were selected. As was found in our
chemical characterization studies, the pu-
rityofthe dyes varies greatly.
ChemicalAnalyse
Comprehensive purity, identity, and stabil-
ity studies were performed on the benzi-
dine congeners and dyes used in the 2-year
chronic studies. Reports on the analyses
performed are on file at the National
Institute of Environmental Health
Sciences. The study chemicals were identi-
fied as 3,3'-dimethylbenzidine dihy-
drochloride, 3,3'-dimethoxybenzidine
dihydrochloride, C.I. Direct Blue 15, C.I.
Acid Red 114, or C.I. Direct Blue 218 by
infrared, ultraviolet/visible, and nuclear
magnetic resonance spectroscopy. The pu-
rities of 3,3'-dimethylbenzidine dihy-
drochloride and 3,3'-dimethoxybenzidine
dihydrochloride were determined to be 99
and 98%, respectively, by elemental analy-
sis, Karl Fischer water analysis, titrations
(nonaqueous amine and neutralization
titrations), thin-layer chromatography, and
high-performance liquid chromatography
(HPLC). Because of its high salt content,
Direct Blue 15 was desalted by dialysis,
which reduced the salt content from ap-
proximately 25 to about 3%. The purity of
the desalted dye was determined to be
about 50%. Approximately 35 impurities
were detected by HPLC analysis account-
ing for about 50% ofthe chromatographic
peak area. No attempt was made to iden-
tify the chromatographic peaks. However,
the chemical was assayed for free benzidine
and 3,3'-dimethoxybenzidine content.
Benzidine could not be detected at levels
greater than 1 ppm in either ofthe two lots
used in the study, whereas 3,3'-dimethoxy-
benzidine was found at 826 and 1310 ppm
in two lots that were sampled.
The dye, Acid Red 114, was desalted by
dialysis, and the salt content reduced from
approximately 14.9 to about 0.9%. The
purity ofthe desalted dye was estimated at
82 to 85%. There were approximately 15
organic impurities observed by HPLC
analysis; these impurities were similar in
structure to the major component, with the
two largest components estimated at 3%
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Figure 1. Generalized synthetic scheme for benzidine (R=H), the benzidine congeners 3,3'- dimethylbenzidine (R=CH3),
and3,3'-dimethoxybenzidine (R=OCH3), and derived azodyes(R'and R"=various aromatic intermediates).
each. In addition, there was approximately
1 to 4% water present in the dye. The level
ofbenzidine detected by HPLC did not ex-
ceed 1 ppm; whereas, 3,3'-dimethylbenzi-
dine was detected at a concentration of
approximately 5 ppm.
Direct Blue 218 contained about 2%
salt after desalting by dialysis. The purity of
the desalted chemical was determined to be
approximately 60%. Over a dozen impuri-
ties were detected by HPLC analysis, ac-
counting for approximately 40% of the
chromatographic peak area. No attempt
was made to identify the chromatographic
peaks, however, the concentrations ofbenzi-
dine and 3,3'-dimethoxybenzidine were de-
termined. Benzidine could not be detected in
either lot at levels greater than 1 ppm. 3,3'-
Dimethoxybezidine was found at levels less
than orequal to 7 ppm.
Dose Formulation
Dose formulations were characterized and
the concentrations confirmed during the
toxicology studies. In all cases, except C.I.
Direct Blue 218, reverse-phase HPLC-UV
systems were used. Detector wavelengths
were 280 nm for 3,3'-dimethylbenzidine
and 3,3'-dimethoxybenzidine; 546 nm for
C.I. Direct Blue 15 and 512 nm for C.I.
Acid Red 114. For C.I. Direct Blue 218,
visible spectroscopy at 622 nm was em-
ployed. Reports on the dose formulation
studies are on file at the National Institute
ofEnvironmental Health Sciences.
Initially, attempts were made to formu-
late 3,3'-dimethylbenzidine dihydro-
chloride and 3,3'-dimethoxybenzidine
dihydrochloride in feed. However, feed for-
mulations were unstable when stored in the
dark in sealed containers at room tempera-
ture, 50C, or -2°C. Drinking water was
then investigated as a vehicle for chemical
administration. Solutions of3,3'-dimethyl-
benzidine dihydrochloride or 3,3'-di-
methoxybenzidine dihydrochloride in
water remained stable for at least 14 days
when stored at either room temperature or
50C. Solutions were also stable for up to 48
hr under simulated animal dosing condi-
tions. During the studies drinking water
formulations were prepared two
times/week and were used immediately or
stored at room temperature for up to 7
days before being used. The drinking water
solutions were analyzed at approximately 4-
week intervals. Of the dose formulations
analyzed, 99% were determined to be
within 10% of the target concentration.
Results of periodic independent analyses
agreed with the results of the toxicology
study laboratory.
The drinking water formulations of
Direct Blue 15 and Acid Red 114 re-
mained stable for at least 21 days when
stored at room temperature. Solutions were
stable for at least 3 days under simulated
dosing conditions including exposure to
normal room light and air. Dose formula-
tions were prepared twice weekly and made
available to the study animals on the day of
mixing. Dose formulations were analyzed
at least once every 4 weeks for the duration
of the studies; all were determined to be
within + 10% ofthe target concentrations.
Direct Blue 218 was insoluble in water
at the required concentrations for the 2-
year studies. Because ofthe solubility limi-
tations, the dose formulations were
prepared by mixing Direct Blue 218 with
feed. Stability tests showed that the formu-
lations were homogeneous and stable for at
least 21 days when stored at room tempera-
ture, and for at least 3 days under simu-
lated animal dosing conditions. Dose
formulations were prepared once every 2
weeks. The formulations used for dosing
were analyzed at least once every 4 weeks;
97% were determined to be within 10% of
the target concentration.
Metabolism and Mechanisms
ofToxicity
As part of the initiative to characterize the
toxicity and carcinogenicity of benzidine
and benzidine-congener based dyes, the
NTP conducted and sponsored studies of
the metabolism of both the dyes and par-
ent compounds. These studies were con-
ducted at the National Center for
Toxicological Research (NCTR) and
through contractual mechanisms. This sec-
tion presents a summary ofthat work, and
includes relevant work done by others
since that time, to more completely de-
scribe the fate and mechanisms of toxicity
ofthese compounds.
Metabolism/Disposition ofDyes
The objectives of metabolism and disposi-
tion studies conducted or supported by the
NTP were to investigate the degree to
which the dyes or parent amines were ab-
sorbed from the gastrointestinal tract, and
to determine the amount of parent amine
eliminated in urine following exposure to
the dyes (Figure 2). The presence of the
parent amine in urine was taken as evi-
dence of exposure of the target tissue for
humans, the urinary bladder. It was further
assumed that results obtained with repre-
sentatives ofeach dye class would be repre-
sentative of the respective classes. That is,
the absence of the release of benzidine, or
the respective congeners, or metabolites of
these compounds, would be taken as evi-
dence that the dyes were not metabolized
to the parent compounds, and that human
risks associated with exposure to the dyes
may not be related to exposure to the re-
spective parent amine. Similarly, release of
the respective parent amine following expo-
sure to most or all ofthe dyes would indi-
cate that exposure to the dyes would entail
risks similar to those associated with the
parent compound. Mixed results would be
taken as evidence that more dyes should be
tested prior to judging the risks associated
with using this class ofcompounds.
The biological reduction of azo com-
pounds to release aromatic amines had
been previously demonstrated by a number
of investigators (6-8) prior to the NTP
studies of benzidine and related dyes.
Further, the metabolism offour benzidine-
based dyes by rhesus monkeys to benzidine
was described in a brief report by Rinde
and Troll (9) in 1975. However, metabo-
lite identification in the studies of Rinde
and Troll were limited to thin-layer chro-
matography versus authentic standards of
benzidine and N-acetylbenzidine.
Therefore the NTP-sponsored studies were
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Figure Z Metabolism ofthe benzidine congener and benzidine dyes (e.g., C.l. Direct Blue 6 ) initially involves azo reduc-
tion in thegastrointestinal tract producing free benzidine orbenzidine congener, and otheraromatic amine by-products.
designed to confirm and extend those ob-
servations by studying seven additional
benzidine dyes, two dimethoxybenzidine-
based and four dimethylbenzidine-based
dyes. The NTP studies also more fully
characterized the metabolism ofthese com-
pounds and confirmed metabolite struc-
tures by gas chromatography and mass
spectral analysis.
Dyes representative of those in use at
the time were selected for metabolism and
disposition studies. Benzidine-based dyes
selected included Direct Orange 1, Direct
Green 1, Direct Orange 8, Direct Black 4,
Direct Brown 2, Direct Blue 2 and Direct
Red 28. The 3,3'-dimethoxybenzidine-
based dyes studied were Direct Blue 15 and
Direct Blue 1. In addition, Direct Blue 25,
Direct Red 2, Direct Red 39 and Acid Red
114, all 3,3'-dimethylbenzidine-based dyes,
were studied. In addition to the dyes, these
studies also included the parent com-
pounds (the structures ofthese compounds
are presented in Table 1).
The dog was chosen as a test species be-
cause, other than humans, it was the only
species known to develop bladder tumors
as a result of benzidine exposure (1). The
rat was chosen for comparative purposes,
and because this species was to be used in
chronic studies ofseveral ofthese dyes.
The objective of the initial studies was
to confirm the metabolism of benzidine
and benzidine-based dyes to the parent
amines. In these initial studies the test
chemicals were administered to dogs at
100 mg/kg in meat balls, and urine was
collected at 24 hr intervals for 3 days. No
benzidine or related compounds were de-
tectable in urine by the third day. Rats re-
ceived similar doses of the dyes by oral
gavage in water daily for 10 days. Urine
from both species was collected over ice
and stored at approximately 20°C.
Concentrations of benzidine, the con-
geners, and known metabolites of these
compounds in urine were determined by
gas chromatography. Concentrations of
benzidine, 3,3'-dimethylbenzidine or 3,3'-
dimethoxybenzidine in the starting dyes
also were determined by gas chromatogra-
phy. In analyses ofboth the urine and the
dyes, the identities of the chromato-
graphic peaks were confirmed by mass
spectrometry (10).
Results ofstudies with dogs established
that the respective free parent amines were
excreted in urine following administration
of each of the benzidine and 3,3'-
dimethoxybenzidine dyes studied, and fol-
lowing administration of Direct Blue 25
and Acid Red 114, two ofthe four 3,3'-di-
methylbenzidine-based dyes. Adminis-
tration of two other 3,3'-dimethyl-
benzidine-based dyes, Direct Reds 2 and
39, did not result in 3,3'-dimethylbenzi-
dine in the urine ofdogs. After administra-
tion of benzidine-based dyes, the amounts
of benzidine excreted were small (about
0.1% of the dose), but they were at least
nine times greater than the amounts of
benzidine administered as contaminants in
the dyes, and were equivalent to the
amount excreted following administration
of neat benzidine. Since dogs do not read-
ily acetylate aromatic amines such as benzi-
dine, free amines were excreted in the
urine. On the other hand, rats readily
acetylate these compounds and excreted
both the free amines and significant
amounts of the N-acetyl metabolites of
benzidine and its congeners (10).
Conclusions that could be drawn from
these studies were that the azo linkages of
most dyes studied were reduced to release
free benzidine or the respective congeners,
which were subsequently excreted in urine.
Azo reduction probably occurred in the in-
testine and, less probably, in liver.
Reduction ofdyes to the parent amines by
anaerobic intestinal bacteria from humans,
monkeys, and rats, was confirmed in a later
report (11). More important, based on the
amount of benzidine or its congeners ex-
creted in urine, it appeared that most dyes
were reduced quantitatively to release the
parent amines to result in exposure of the
target tissue, the urinary bladder.
As a result of their quantitative reduc-
tion to the parent amine, exposure to ben-
zidine-, or benzidine-congener-based dyes
appears to result in exposure to concentra-
tions of benzidine (or congener) that are
comparable to those that occur following
exposure to equivalent amounts of free
benzidine (or congener). Furthermore, the
consistency of results obtained with benzi-
dine and related dyes implies that their re-
duction to release the respective parent
amine is probably a general phenomenon.
That is, similar results and risks associated
with exposure to benzidine should be an-
ticipated with most dyes based on benzi-
dine and its congeners (10). These results
also imply that benzidine detected in urine
from workers exposed to benzidine-based
dyes was probably derived from the dyes,
rather than from traces of benzidine pre-
sent in the dyes as a contaminant (12). The
significance of this finding is that the pro-
duction and use of benzidine and related
dyes carries inherent risks which cannot be
overcome by producing and using dyes
which contain less of the respective parent
amine as a contaminant.
BenzidineMetabolism
Neither benzidine nor its congeners are
thought to be carcinogenic prior to meta-
bolic activation. The presence ofbenzidine
or its congeners in urine was considered
significant only because it demonstrated
that the target tissue in humans, urinary
bladder, was exposed to a potential carcino-
gen following exposure to the dyes. The
speculated necessity for metabolic activa-
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tion was consistent with the report that
benzidine is a bacterial mutagen only when
activated by a liver enzyme preparation
(13). The first in vitro study of benzidine
metabolism demonstrated that benzidine is
acetylated to form N-acetylbenzidine,
N,N'-diacetylbenzidine, and N-hydroxy-
N,N'-diacetylbenzidine (14). These studies
further implied that the latter metabolite
was somehow involved in the alkylation of
DNA.
In an early study ofcomparative metab-
olism of benzidine in several species
Clayson et al. (15) demonstrated that the
dog was the only species studied that did
not form N-acetylbenzidine when adminis-
tered the parent compound. In another
early study, Sciarini and Meigs (16) iso-
lated the N- and 0-glucuronides as well as
the N-and 0-sulfate metabolites from dogs
and other species administered benzidine.
A more thorough study ofbenzidine dispo-
sition and metabolism in dogs and rats by
Lynn et al. (17) demonstrated that benzi-
dine is readily absorbed from the gastro-
intestinal tract, metabolized extensively,
and rapidly excreted in urine and feces.
Excretion in feces exceeded that in urine by
2- to 3-fold, and less than 10% ofthe dose
remained in the tissues, primarily liver,
after 3 days.
The use of radiolabeled benzidine and
HPLC analysis permitted Lynn et al. (17)
to detect at least 17 distinct metabolite
peaks in urine following oral administra-
tion to rats. Benzidine accounted for less
than 2% ofthe total radiolabel excreted in
urine. The major metabolites excreted in
bile and urine were isolated and identified
as glucuronide conjugates ofbenzidine, N-
acetylbenzidine, NN-diacetylbenzidine, 3-
hydroxy-N,N'-diacetylbenzidine, and free
N-acetyl- and N,N'-diacetylbenzidine. 3-
Hydroxy-N,N'-diacetylbenzidine was the
major metabolite excreted in urine and
bile. A study of the mutagenicity of these
metabolites in the Salmonella/liver S9 sys-
tem showed that both the mono- and di-
acetylated metabolites were approximately
10 times as mutagenic as benzidine. The
most mutagenic metabolite isolated in this
study, N-hydroxy-NN'-diacetylbenzidine
glucuronide, was approximately 100 times
more potent a mutagen than the parent
compound when incubated with P-
glucuronidase to release the hydroxylated
diacetylamine (18).
Lynn et al. (17) measured concentra-
tions of benzidine-derived radioactivity in
all the major tissues at 0.5, 1, 2, 4, 8, 24,
and 72 hr after dosing. Radioactivity was
concentrated only in liver, which contained
the highest concentrations at every time
point. Extraction and analysis ofradiolabel
from liver determined that very little ofthis
radioactivity was free benzidine, but ap-
proximately half was in the form of two
metabolites, N-acetyl- and NN'-diacetyl-
benzidine. The remainder was in the form
of unidentified polar metabolites. NN'-
Diacetylbenzidine accounted for approxi-
mately 80% of the benzidine-derived
radioactivity in blood at the early time
points; however, concentrations at later
time points were too low to permit accu-
rate analysis. Studies with isolated, perfused
rat livers demonstrated that all of the
metabolites isolated and identified from
whole animals could be formed by the
liver. Further, some of these metabolites
were themselves subject to additional me-
tabolism, including the rapid reduction of
the most mutagenic metabolize, N-hy-
droxy-N,N'-diacetylbenzidine, to the less
mutagenic NN'-diacetylbenzidine (18).
Metabolism and disposition of 3,3'-
dimethoxybenzidine in intact rats was simi-
lar to that reported for benzidine, except
that the 3-methoxy groups provided addi-
tional sites for metabolic attack and re-
sulted in more rapid and more extensive
metabolism (19). The most mutagenic
metabolize isolated in this study was N-
acetyldimethoxybenzidine.
Benzidine Interactionwith DNA
As mentioned above, benzidine is believed
to be carcinogenic only following meta-
bolic activation. Like other carcinogenic
aromatic amines, such as 2-naphthylamine
and 2-acetylaminofluorene, benzidine and
its congeners were presumed to be metabo-
lized to intermediates which reacted with
DNA to result in mutations and carcino-
genicity. Evidence for the increased muta-
genicity of benzidine following metabolic
activation was provided by the studies of
Morton et al. (14), who reported nucleic
acid binding of benzidine; and Lynn et al.
(17), who reported that the glucuronide of
N-hydroxy-NN'-diacetylbenzidine was as
much as 100 times more mutagenic in the
Salmonella/liver S9 assay than benzidine.
Martin et al. (20) studied the metabolism
and covalent binding of benzidine and a
benzidine metabolite, N-acetylbenzidine,
in vitroand in vivo in the rat. They isolated
and identified a product of DNA alkyla-
tion, N-(deoxyguanosin-8-yl)-N'-acetyl-
benzidine, which could have been formed
from either N-acetylbenzidine or NN'-di-
acetylbenzidine, both ofwhich are formed
by rat liver (18) and excreted in urine (17).
Following their isolation ofa product of
benzidine acetylation of DNA, Martin et
al. (21) demonstrated that this adduct is
readily formed in vivo by rats dosed with
benzidine, N-acetylbenzidine or a benzi-
dine-based dye, Direct Blue 6. Only a trace
ofbinding was detected following adminis-
tration of NN'-diacetylbenzidine which
implied that this metabolite may not be the
precursor to N-hydroxy-NN-diacetylben-
zidine, previously reported to be a potent
bacterial mutagen (17). Subsequent work
using enzyme preparations from rat and
mouse liver provided data to support the
hypothesis that N-hydroxy-NN'-diacetyl-
benzidine is the proximate carcinogen in
these species, because of its capacity to
alkylate DNA. This work also demon-
strated that this metabolite is formed from
N'-hydroxy-N-acetylbenzidine, rather than
N,N'-diacetylbenzidine (22).
The target organ for benzidine car-
cinogenesis in humans is the urinary blad-
der, and the best experimental animal to
model this lesion is thought to be the dog.
Unlike rats and mice, dogs do not acety-
late benzidine or other arylamines known
to induce bladder cancer (2-1. Therefore,
the causative agent in benzidine carcino-
genesis in the dog was not thought to be
the hydroxyacetylamine metabolite specu-
lated to account for carcinogenesis in ro-
dent studies.
Beland et al. (24) studied the formation
ofDNA adducts in urinary bladder ofdogs
following oral administration of a number
of known carcinogenic aromatic amines,
including benzidine and N-acetylbenzi-
dine. Their studies demonstrated a positive
correlation ofthe degree ofbinding of car-
cinogenic aromatic amines to bladder
DNA with the potency of the respective
compounds. Further, of the known car-
cinogens studied, binding to DNA in the
dog bladder following administration of
benzidine and N-acetylbenzidine was
equivalent to that observed following ad-
ministration of two other potent bladder
carcinogens, 2-naphthylamine and 4-nitro-
biphenyl. These investigators proposed that
N-hydroxylamines account for the carcino-
genicity ofeach ofthese compounds in the
urinary bladder of dogs, and speculated
that these reactive intermediates are formed
in the liver and transported to the bladder
as glucuronide conjugates which hydrolyze
in the weakly acidic urine to release the re-
active intermediate (24).
A more recent publication has demon-
strated that, in the dog, benzidine may also
be transported to the bladder as a glu-
curonide conjugate which could be hy-
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drolyzed to release free benzidine (25).
Later work by members ofthis same group,
however, demonstrated that benzidine is
also metabolized to a reactive intermediate
by arachidonic acid-dependent prosta-
glandin H synthase and that prostaglandin
H synthase is present in high concentra-
tions in dog bladder (26,27). The reactive
intermediate formed by prostaglandin H
synthase, benzidine diimine, was proposed
to react directly with DNA to form an
adduct, N-(deoxyguanosin-8-yl)benzidine,
which was later isolated and identified
(28). In studies ofa series ofhuman tissues
the urinary bladder was shown to be rich in
prostaglandin H synthase, and among the
aromatic amines studied, benzidine was
shown to be the optimum substrate for this
enzyme (29). Thus, the presence of
prostaglandin H synthase in dog and
human urinary bladder probably accounts
for the activation and carcinogenicity of
benzidine in this tissue.
Summary
Studies of the metabolism and disposi-
tion of dyes derived from benzidine and
benzidine congeners established that, fol-
lowing ingestion, the azo linkages of
these compounds are reduced, probably
by bacteria in the intestines, to release
the parent amines. Reduction ofthe dyes
to the respective free amines appears to
be nearly complete, therefore, ingestion
of most benzidine and related dyes is
thought to be comparable to ingestion of
an equivalent amount of the respective
free amine. The free amines (benzidine
and its congeners) are absorbed readily
from the gastrointestinal tract, rapidly
and extensively metabolized and excreted
in both urine and feces. The degree of
benzidine excretion in urine by experi-
mental animals exposed to dyes, and the
actual detection of benzidine in urine of
workers in the dye industry, strongly
support the potential for exposure of
human urinary bladder to this known
bladder carcinogen following exposure to
the respective dyes.
The probable reactive intermediate
which accounts for the carcinogenicity of
benzidine in rodents is N-hydroxy-NN'-
diacetylbenzidine. This reactive interme-
diate is formed in liver and is probably
transported to target tissues in blood or
urine. Dogs do not acetylate benzidine
and humans acetylate benzidine less
readily than rodents; therefore, the reac-
tive intermediates of benzidine vary with
species. Metabolism to a reactive inter-
mediate by dogs and humans may also
occur in liver, but urinary bladder car-
cinogenicity is more probably mediated
by the action of prostaglandin H syn-
thase in the target tissue. Prostaglandin
H synthase forms a diimine metabolite
which reacts directly with DNA in the
bladder.
Mutagenicity
Salmonella mutagenicity studies were
prompted by the fact that benzidine con-
gener dyes were not uniformly and reliably
positive in oxidative in vitro mutagenicity
assays. It was believed that the dyes re-
quired reductive cleavage to yield the par-
ent amine in order to be mutagenic. The
objectives of the mutagenicity portions of
the initiative were to establish an optimal
protocol for the reductive cleavage of the
dyes, and evaluate the mutagenic effects of
benzidine-congener-derived dyes. A part of
this latter activity was to determine if the
mutagenicity of the dyes was attributable
to the parent amine metabolites, or ifactiv-
ity was either quantitatively or qualitatively
influenced by the chromophore portions of
the molecules. In addition, the mutagenic-
ity of the benzidine and benzidine-con-
gener metabolites found in the urine of
dosed rats was investigated. It was reasoned
that the demonstration of a genotoxic po-
tential for these urinary metabolites would
increase the confidence in predictions of
carcinogenicity after short-term oral ad-
ministration ofthese dyes in laboratory an-
imals. These studies would also provide
additional information regarding the meta-
bolic activation ofthe dyes.
Three Salmonella mutagenesis testing
protocols were used. All dyes were first
tested (under code) using a standard, aero-
bic preincubation procedure in Salmonella
strains TA98, TA100, TA1535, and
TA1537, with and without metabolic acti-
vation. S9 fractions derived from the livers
of Aroclor 1254-treated male Sprague-
Dawley rats and Syrian hamsters were used.
Some dyes were also tested using strain
TA97. The detailed test procedure and cri-
teria for a positive response are in
Mortelmans et al. (30) and Zeiger et al.
(31,32).
The mutagenic and nonmutagenic dyes
were also tested following treatment under
reducing conditions to liberate the parent
amine. Equimolar concentrations of the
parent benzidine congeners were tested in
parallel with the dyes. The FMN reduction
protocol of Prival and Mitchell (33) and
the cecal flora reduction procedure ofReid
et al. (34,35) were used. In the Prival pro-
cedure, the dyes were preincubated using
the standard aerobic procedure except that
the liver S9 and cofactors were supple-
mented with NADH and FMN to provide
reducing conditions (33,36). The cecal
flora reduction procedure employed a
washed suspension of rat cecal flora. The
dye was added to this culture and incu-
bated overnight under anoxic conditions.
The incubation mixture was extracted with
ethyl acetate, dissolved in DMSO, and
tested for mutagenicity using the standard
aerobic preincubation procedure (34). All
reduction experiments were performed
using strains TA98 and TA1538, because
these strains are more responsive to the
mutagenic effects of benzidine, 3,3'-
dimethoxybenzidine, and 3,3'-dimethyl-
benzidine than the other tester strains.
MutagenicityoftheDyes
With the exception of Direct Blue 218
(30,34) and Pigment Yellow 12 (31,34),
all dyes tested were mutagenic in
Salmonella, and produced frameshift muta-
tions in strains TA98 or TA1538 when
tested under conditions that fostered re-
duction of the azo bonds (Table 2)
(30-34). Only Direct Black 38 (30,34)
and Direct Blue 2 (30) were mutagenic
without activation. The dyes that were mu-
tagenic with the standard aerobic S9 prepa-
ration generally gave weaker responses than
they did following azoreduction. The posi-
tive responses with the standard S9 mix
alone showed that this metabolic activation
preparation was able to induce low levels of
azoreduction or that the dye sample con-
tained impurities that could be activated to
mutagens without azoreduction.
Many ofthe dyes tested had high levels
ofimpurities, although the specific impuri-
ties were not identified. It was not deter-
mined to what extent any mutagenicity
seen under aerobic conditions was due to
bacterial reduction ofthe dye, and what ex-
tent was due to mutagenic impurities.
Mutagenic PotencyofReducedDyes
and Congeners
In the azoreduction protocols, the various
dyes were tested in parallel with equimolar
concentrations of the parent benzidine
congeners (34). This was done to compare
the level of mutagenicity induced by the
parent amine with the mutagenicity in-
duced by an equimolar concentration of
amine released from the dye. Benzidine was
more mutagenic with hamster than rat S9;
3,3'-dimethoxybenzidine was more muta-
genic when tested with rat than hamster
S9; and 3,3'-dimethylbenzidine gave equiv-
alent results with both S9s. 3,3'-
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Table 2. Summary of Salmonellamutagenicity'
Metabolic activationb
Congener/dye % Purity None S9 FMN Cecal
Benzidine >99 - + + +
Direct Black 38 66 + + + +
Direct Blue 2 46 + + + nt
Direct Blue 6 60 - - + +
Direct Brown 2 87 - nt nt
Direct Brown 95 89 - + +
Direct Green 1 - - +w nt nt
3,3'-Dimethylbenzidine 99 - + + +
Acid Red 114 82 - + + +
Direct Blue 25 - - - + +
Direct Blue 53 69 - nt nt
Direct Red 2 >92 - - + +
Direct Red 39 - - - + +
3,3'-Dimethoxybenzidine 98 - + + +
Direct Blue1 - - - + nt
Direct Blue 8 30 - - + +
Direct Blue 10 48 - - + +
Direct Blue 15 50 - - + +
DirectViolet32 - - - + +
3,3'-Dihydroxybenzidine - + nt nt
DirectBlue 218 60
3,3'-Dichlorobenzidine >99 + + + +
PigmentYellow 12 - - -
*None, no metabolic activation conditions used; S9, standard(aerobic) preincubation test procedure; FMN, FMN-sup-
plemented S9 for reductive metabolism; cecal, ratcecal flora suspension foranaerobic metabolism; -, not mutagenic;
+, mutagenic; +w, weakly mutagenic; ? equivocal mutagenic response; nt, not tested. aSummary of Salmonella muta-
genicity results with the different benzidine congener dyes and differing metabolic activation systems. The data sup-
porting these summaries are from Yamazoe et al. (27), Kadlubar et al. (28), Flammang et al. (29), Mortelmans et al.
(30), and Zeiger etal. (31,32,
Dihydroxybenzidine, a putative metabolite
of Direct Blue 218, was more mutagenic
with hamster than with rat liver S9 in
Salmonella strain TA98 (E Zeiger et al. un-
Table 3. Estimated amount of benzidine congener ordye consumed in long-term studies.
Males Females
Benzidine congener Low-dose Mid-dose High-dose Low-dose Mid-dose High-dose
Rats
3,3'-Dimethylbenzidine.2HCI
Drinking water, ppm 30 70 150 30 70 150
Dose, pmole/kg/day8 5 13 74 6 20 54
3,3'-Dimethoxybenzidine.2HCI
Drinking water, ppm 80 170 330 80 170 330
Dose, pmole/kg/day 18 38 6 22 44 72
Cl. Acid Red 114
Drinking water, ppm 70 150 300 150 300 600
Dose, pmole/kg/day 4 9 23 11 25 82
C.l. Direct Blue 15
Drinking water, ppm 630 1,250 2,500 630 1,250 2,500
Dose, pmole/kg/day 62 89 215 49 100 198
C.l. Direct Blue 218
Feed, ppm 1,000 3,000 10,000 1,000 3,000 10,000
Dose, pmole/kg/day 33 100 335 37 109 374
Mice
C.l. Direct Blue 218
Feed, ppm 1,000 3,000 10,000 1,000 3,000 10,000
Dose, pmole/kg/day 96 295 1,292 117 358 1,810
aBased on water or feed consumption measurements during the last year of study, and molecular weight for con-
geners ormajor component ofdye. The molecularweight for each congener or major component is: 3,3'-dimethylben-
zidine dihydrochloride, 285; 3,3'-dimethoxybenzidine dihydrochloride, 317; C.l. Acid Red 114, 830; C.l. Direct Blue 15,
993; C.l. Direct Blue 218, 1090.
published data). 3,3'-Dichlorobenzidine
was the most potent mutagen, and the only
congener that was mutagenic without S9
activation. There did not appear to be a
correlation between the mutagenic re-
sponses induced by the parent amines and
those induced by the reduced dyes. For
some dyes, the reduction products were
more mutagenic than an equimolar quan-
tity ofthe amine; for other dyes the oppo-
site was seen. These results may be related
to the possible mutagenic or inhibitory ef-
fects ofthe other moieties released from the
dye during azoreduction, to mutagenic im-
purities in the dye preparation, or to in-
complete reduction ofthe dye (34).
MutagenicityofMetabolites
The N-acetylated and the NN-diacetyl-
ated urinary metabolites of benzidine,
3,3'-dimethylbenzidine and 3,3'-di-
methoxybenzidine were mutagenic in
Salmonella strains TA98 and TA1538; the
N-acetylated metabolites were also muta-
genic in TA100 (3-5 These results show
that, with the exception of Direct Blue
218 and Pigment Yellow 12, all dyes tested
that can be reduced to their benzidine
congeners, are mutagenic in Salmonella.
The mutagenic responses obtained with
the rat cecal preparations show that the
dyes can be reduced to their constituent
benzidine congeners by the gut flora as ef-
fectively as by liver preparations under re-
duced conditions. In addition, the results
show that these cecal preparations do not
further metabolize the resulting aromatic
amines to products that will not be muta-
genic upon subsequent aerobic metabolism
by liver enzymes.
The azo linkages in Direct Blue 218
also appeared to be reduced by the
NADP/FMN-fortified rodent liver prepa-
rations and by the cecal extract, as judged
by the change in visible color intensity,
but the resulting product was not muta-
genic. This may indicate that the reduc-
tion of this dye does not release the free
amine, but a copper complex of this
amine with the chromophore or to 3,3'-
dihydroxybenzidine. In the Reid et al.
study (34), approximately 50% of the
Direct Blue 218 was reduced by rat cecal
bacteria as determined by spectrophoto-
metric analysis. However, comparison of
the mutagenic responses of this congener
to the test responses of Direct Blue 218
showed that the highest dose tested of
Direct Blue 218 was 0.5 jimole/plate,
whereas the mutagenic response of 3,3'-
dihydroxybenzidine were seen only at
doses above 1.5 pmole/plate. Pigment
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Yellow 12 did not appear to be reduced,
probably as a consequence ofits insolubil-
ity, and was not mutagenic.
The question ofthe mutagenicity ofthe
chromophore moieties ofthe dyes was not
addressed. In a number ofinstances, how-
ever, the mutagenic responses following re-
duction of the dye and subsequent
oxidative metabolism ofthe reduced prod-
ucts was greater than that obtained follow-
ing similar treatment of the parent
congener amine (33,36). This suggests
that the chromophore was also mutagenic.
Summary
Mutagenicity studies provided evidence
that the benzidine- and benzidine con-
gener-derived dyes require reductive me-
tabolism before they are mutagenic. All
soluble dyes tested, with the exception of
Direct Blue 218 (copper chelated), pro-
duced frameshift mutations in Salmonella
when tested under conditions that fostered
reduction of the azo bonds. Only Direct
Black 38 and Direct Blue 2 were muta-
genic without activation, possibly due to
the presence of mutagenic impurities in
these dye preparations. This information
supports the results of metabolism studies
relative to the mechanisms ofgenotoxic ac-
tion, and increases confidence in predicting
the carcinogenicity ofthese chemicals.
Carcinogenesis
ChronicCarcinogenicityTesting
The objectives of the in vivo carcinogenic-
ity studies were to: conduct definitive stud-
ies of the carcinogenicity of orally
administered 3,3'-dimethylbenzidine and
3,3'-dimethoxybenzidine in rats; assess the
carcinogenicity of orally administered pro-
totypical benzidine congener derived dyes;
develop dose-response relationships for the
carcinogenicity of the dyes and the parent
amines; determine similarities in the quali-
tative nature ofthe responses to the parent
amines and the derived dyes; and assess the
carcinogenicity of a metallized benzidine
congener dye (Direct Blue 218).
Five chemicals were evaluated in the 2-
year carcinogenicity studies: 3,3'-dimeth-
oxybenzidine dihydrochloride, and
3,3'-dimethylbenzidine dihydrochloride
(benzidine congeners), Direct Blue 15 (a
representative 3,3'-dimethoxybenzidine-
based dye), Acid Red 114 (a representative
3,3'-dimethylbenzidine-based dye) and
Direct Blue 218 a metallized 3,3'-
dimethoxybenzidine-based dye). The oral
route of administration was selected to
maximize the chances ofdetecting systemic
Table 4. Summary of survival in long-term studies.
Week Male rats Female rats
3,3'-Dimethylbenzidine dihydrochloride
Exposure, ppma 0 30 70 150 0 30 70 150
1 70 45 75 70 70 45 75 70
13 70 45 74 70 70 45 75 70
41 60b 44 72 44b 60b 45 71 51b
57C 60 42 57 0 59 40 42 16
3,3'-Dimethoxybenzidine dihydrochloride
Exposure, ppm 0 80 170 330 0 80 170 330
1 70 45 75 70 70 45 75 70
13 69 45 75 70 70 45 75 70
41 59b 44 75 59 b 60b 45 73 57b
57 59 42 68 53 60 44 52 40
69 58 42 57 39 59 40 34 18
93d 45 8 0 0 45 15 6 0
C.l. Acid Red 114
Exposure, ppm 0 70 150 300 0 150 300 600
1 70 45 75 70 70 45 75 70
13 70 45 75 70 70 45 74 70
41 59b 45 75 60b 60b 45 73 56b
57 58 44 74 57 60 45 71 44
69 45b 32b 62b 43b 49b 32b 57b 14
93e 24 15 26 1 35 13 6 0
C.l. Direct Blue 15
Exposure, ppm 0 630 1250 2500 0 630 1250 2500
1 70 45 75 70 70 45 75 70
13 70 45 75 70 70 45 75 70
57 60b 45 75 57b 60b 45 74 60b
69 47b 31b 59b 36b 49b 33b 56b 38b
971 37 8 13 2 41 13 25 4
aConcentration in drinkingwater.bTen animals removed at 9 and/or 15 monthsfor interim evaluation.cStudyterminated
at 15 months. d Study terminated at 21 months. eStudy terminated at 24 months. fStudy terminated at 22 months.
effects associated with chemical administra-
tion. 3,3'-Dimethylbenzidine, Acid Red
114, 3,3'-dimethoxybenzidine, and Direct
Blue 15 were all studied using the same ex-
perimental design. Because of the instabil-
ity of 3,3'-dimethylbenzidine and
3,3'-dimethoxybenzidine in feed, all chem-
icals, except Direct Blue 218, were admin-
istered in drinking water. Direct Blue 218
was not soluble in drinking water, so it was
administered in feed. Because long-term
studies of3,3'-dimethylbenzidine and 3,3'-
dimethoxybenzidine in mice were per-
formed at the National Center for
Toxicology Research (37,38), only male
and female rats were used in the studies de-
scribed here. Rats and mice of both sexes
were used in the Direct Blue 218 study.
All studies utilized untreated controls
and three dosed groups of each sex. These
experimental groups consisted of"core" an-
imals intended for 24 months oftreatment
plus additional animals designated for in-
terim evaluations at 9 and 15 months. For
all, except the Direct Blue 218 study, the
allocation of animals in each group fol-
lowed a procedure recommended by
Portier and Hoel (39). The 9 month in-
terim evaluations were performed in each
study; however, because of excessive early
cancer-related mortality in the 3,3'-
dimethoxybenzidine and 3,3'-dimethylben-
zidine studies, the 15 month evaluations
were not performed and the animals origi-
nally designated for interim evaluation
were incorporated into the core group. The
Direct Blue 218 studies in both rats and
mice followed a standard design with 50
core animals per group and 10 additional
animals per group designated for interim
evaluation at 15 months; there was no 9
month interim evaluation.
Dose selections for the carcinogenicity
studies were based on the results ofexperi-
ments in which groups of 10 male and 10
female rats received test compound in their
drinking water or food for from 2 to 13
weeks. Evaluative criteria used to assess the
toxicologic effects of the chemicals during
the prechronic studies included body
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Table 5. Summary of survival in long-term studies of C.I. Direct Blue 218.
Exposure,
ppma 0 1000 3000 10000 0 1000 3000 10000
Week Male mice Female mice
1 60 60 60 60 60 60 60 60
13 58 60 60 60 59 60 60 59
41 58 60 60 60 57 60 60 58
57 57 60 60 60 56 60 60 58
69 48b 49b 501 501 461 501 491 471
93c 46 49 48 48 40 45 48 43
Week Male rats Female rats
1 60 60 60 60 60 60 60 60
13 60 60 60 60 60 60 60 59
41 59 60 60 60 59 60 60 57
57 59 59 59 59 59 59 59 56
69 48b 49b 49b 47b 47b 47b 48b 46b
93c 36 40 44 37 43 41 38 35
aConcentration in lead. bTen animals removed at 9 months for interim evaluation. CRat and mouse studies were termi-
nated at24months
weight gain, food and water intake, grossly
observable signs, mortality, and micro-
scopic evidence oforgan toxicity.
Experimental animals had free access to
food and water throughout the duration of
the experiment. In experiments in which
the drinking water was used as the vehicle
for the test material, water consumption
was measured weekly; weekly food con-
sumption was measured when food was the
dosing vehicle. Animals were observed
twice daily for morbidity or mortality.
Clinical signs and body weights were
recorded at regular intervals. All animals
were subjected to a complete necropsy. A
complete histologic evaluation, consisting
of microscopic examination of approxi-
mately 40 tissues and all gross lesions, was
performed on all animals except the low-
and mid-dose animals from the 15 month
interim evaluations of Acid Red 114,
Direct Blue 15, and Direct Blue 218. Only
gross lesions and selected tissues were ex-
amined in these groups.
Incidences of neoplasms in dosed and
control groups were compared statistically
using survival adjusted analyses. The life
table test, a procedure appropriate for
rapidly lethal tumors, was used for
mononuclear cell leukemia and Zymbal's
gland tumors, both neoplasms that are
rapidly fatal. Incidences ofother neoplasms
in all but the 3,3'-dimethylbenzidine and
3,3'-dimethoxybenzidine studies were ana-
lyzed by using the logistic regression test.
Significantly reduced survival in the 3,3'-
dimethylbenzidine and 3,3'-dimethoxyben-
zidine studies compromised the power of
logistic regression so the Fisher exact test
utilizing the effective number of animals
was employed for these two studies. The
effective number of animals is the number
of animals that survived until the appear-
ance ofthe initial tumor.
Two- andThirteen-WeekStudies
In general, pronounced effects were not
seen in the 2-week or 13-week studies.
Dose-related reductions in water consump-
tion were observed in the dosed water stud-
ies and reduced feed consumption was seen
in the dosed feed study. Both effects pre-
sumably were due to poor palatability
caused by the presence of the test com-
pound. Reduced body weight gains were
observed at the higher dose levels in all
studies. This effect was presumed to be sec-
ondary to reduced water or food consump-
tion. A few chemical related deaths
occurred in rats in the highest dose groups
during the 2-week studies of3,3'-dimethyl-
benzidine and during the 13-week studies
of 3,3'-dimethylbenzidine and Direct Blue
15.
The most common chemical-related le-
sions observed in rats treated with each of
the compounds for 13 weeks were a mild
degree of hepatocyte degeneration and
necrosis, and degeneration ofrenal tubules.
Hepatocyte hypertrophy (enlargement) and
necrosis were seen in the livers of mice
from the 13-week Direct Blue 218 study.
The results of these studies have been re-
ported in detail elsewhere (40-46).
Two-YearStudies
Concentrations of 3,3'-dimethylbenzidine,
3,3'-dimethoxybenzidine, Acid Red 114,
and Direct Blue 15 added to the drinking
water during the chronic study are shown
in Table 3. The estimated amounts of
chemicals consumed, based on measured
water consumption, are also shown in
Table 3. In general, doses were highest for
Direct Blue 15 followed by 3,3'-
dimethoxybenzidine, and with lower con-
sumptions of Acid Red 114 and
3,3'-dimethylbenzidine. Females typically
consumed somewhat higher doses of
chemicals than did males.
The survivals of male and female rats
dosed with either 3,3'-dimethylbenzidine,
3,3'-dimethoxybenzidine, Acid Red 114,
Direct Blue 15, or Direct Blue 218 are
summarized in Tables 4 and 5. The admin-
istration of each of these compounds sig-
nificantly reduced the survival ofboth sexes
of rats. These significant increases in mor-
tality were considered to be due to in-
creased incidences of chemical-induced,
lethal neoplasms. Because ofthe high inci-
dence of tumors and decreased survivals,
the 3,3'-dimethylbenzidine and 3,3'-
dimethoxybenzidine studies were termi-
nated at 15 and 21 months, respectively,
and the Direct Blue 15 study was termi-
nated at 22 months. Despite significantly
reduced survivals in both sexes, the Acid
Red 114 study was continued until the
scheduled termination (24 months).
Nonneoplastic Lesions
Chemical-related nonneoplastic lesions
were observed in the livers and kidneys in
some studies. The livers ofmale and female
rats treated with all the benzidine com-
pounds except Direct Blue 218 had in-
creased incidences of foci of cellular
alteration, cystic degeneration, hepatocyte
degeneration, necrosis, and regeneration.
Increased incidences of foci of cellular al-
teration were observed in mice treated with
Direct Blue 218. The severity ofnephropa-
thy, a common degenerative change of the
kidney in aging F344 rats, was increased in
treated males and females from the 3,3'-di-
methylbenzidine study, and in treated fe-
males from the Acid Red 114 study. In
addition, foci of hyperplasia, presumably
preneoplastic changes, were seen in the
preputial, clitoral, and Zymbal's glands in
the 3,3'-dimethylbenzidine, 3,3'-dimeth-
oxybenzidine, Acid Red 114, and Direct
Blue 15 studies, and in the lung in the
3,3'-dimethylbenzidine and Acid Red 114
studies.
NeoplasticLesions
3,3'-Dimethylbenzidine, 3,3'-dimethoxy-
benzidine, Acid Red 114, and Direct Blue
15 all caused a similar spectrum ofneoplas-
tic lesions (Tables 6 to 8). The primary
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Table 6. Treatment-related neoplastic responses: skin, Zymbal's gland, liver and oral cavity.
Male rats Female rats
3,3'-Dimethylbenzidine dihydrochloride
Exposure, ppm
Skin
Basal cell
Sebaceous gland
Squamous cell
Keratoacanthomas
Zymbal's gland
Liver
Oral cavity
0 30 70 150
0/60
0/60
0/60
1/60
1/59
0/60
0/60
11/45
0/45
2/45
1/45
3/45
0/45
0/45
54/5
7/75
17/75
8/75
32/5
4/75
7/75
0 30 70 150
30/60
5/60
27/60
5/60
36/59
5/60
5/60
0/60
0/60
0/60
0/60
0/57
0/60
0/60
3/45 10/75
0/45 o05
3/45 9/75
0/45 o0/5
6/44 32/73
0/45 7/74
3/45 9/75
3,3'-Dimethoxybenzidine dihydrochloride
Exposure, ppm
Skin
Basal cell 2/I
Sebaceous gland 0/I
Squamous cell 0/E
Keratoacanthomas 1/I
Zymbal's gland 0/'
Liver 1/A
Oral cavity 1/A
C.l. Acid Red 114
Exposure, ppm
Skin
Basal cell 1/'
Sebaceous gland 1/'
Squamous cell 1/'
Keratoacanthomas 1/'
Zymbal's gland 0/I
Liver 2/'
Oral cavity 0/!
0 80 170 330
'60 32/45
'60 2/45
'60 13/45
'60 1/45
'59 10/45
'60 4/45
'60 8/45
54/75
3/5
28/75
8/75
25/75
7/74
1O/7
0 80 170 330
40/60
2/60
22/60
5/60
30/60
8/60
11/60
0/60
0/60
0/60
0/60
1/60
0/60
2/60
0 70 150 300
'50 5/35
'50 1/35
'50 2/35
'50 1/35
'50 0/35
'50 2/35
'50 0/35
28/65
5/65
11/65
4/65
8/65
15/65
1/65
4/45
0/45
0/45
0/45
12/45
1/44
2/45
3/75
o0/5
o07
o0/5
21/75
o07
6/5
0 150 300 600
32/50
6/50
9/50
7/50
7/50
20/50
2/50
0/50
0/50
0/50
0/50
0/50
0/50
0/50
4/35 7/65
0/35 -
0/35 -
0/35 -
3/35 18/65
3/35 8/65
0/35 0/35
C.l. Direct Blue 15
Exposure, ppm
Skin
Basal cell
Sebaceous gland
Squamous cell
Keratoacanthomas
Zymbal's gland
Liver
Oral cavity
0 630 1250 2500
2/50 9/35
0/50 1/35
2/50 4/35
2/50 1/t35
1/50 5/35
0/50 6/35
1/50 10/35
27/65
7/65
11/65
7/65
10/65
9/65
24/65
0 630 1250
28/50
3/50
19/50
2/50
20/50
11/50
17/50
0/50
0/50
0/50
0/50
0/50
0/50
2/50
0/35 0/65
0/35 0/65
2/35 6/65
0/35 0/65
4/35 11/65
0/35 2/65
4/35 19/65
-, Not determined. aConcentration in drinking water.
chemical related neoplasms were tumors of
the skin, Zymbal's gland, oral cavity ep-
ithelium, liver, preputial/clitoral glands,
and intestines ofboth males and females. A
few ofthese neoplasms were seen as early as
the 9-month interim sacrifices, and the
numbers of tumors at the various sites in-
creased as the studies progressed. The mi-
croscopic appearance ofthe chemical-related
neoplasms was similar in all studies.
While we found a wide variety of tu-
mors in our studies, Robens et al. (2) re-
ported only liver involvement after
administration of the benzidine-derived
dyes. It is unlikely that the 13-week studies
reported by Robens et al. were long enough
for a full expression of toxicity, and there-
fore a comparison ofthe studies is difficult
to make. By way of contrast, however, we
found no evidence ofhepatocarcinogenicity
during the 13-week studies on the congeners
or dyes.
All four chemicals significantly in-
creased the incidence of a variety ofepithe-
lial neoplasms of the skin in both sexes of
rats. These skin tumors included adenomas
and carcinomas ofthe basal cells and seba-
ceous glands, squamous cell papillomas and
carcinomas, and keratoacanthomas.
Neoplasms of the Zymbal's glands in-
cluded adenomas and carcinomas, with
carcinomas being by far the more common
of the two. Carcinomas were highly inva-
sive and occasionally metastasized.
Chemical related neoplasms ofthe oral cav-
ity consisted of squamous cell papillomas
and carcinomas originating from the strati-
fied squamous epithelium. Microscopically,
these neoplasms resembled the squamous
cell neoplasms ofthe skin. Neoplastic nod-
ules and hepatocellular carcinomas oc-
curred as a chemical related effect in the
livers oftreated male and female rats ("neo-
plastic nodule" was the term used previ-
ously for neoplasms now classified as
hepatocellular adenomas). Adenomatous
polyps and adenocarcinomas of the small
and large intestine, neoplasms rarely seen
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9/60
0/60
12/60
0/60
42/60
4/60
13/60
2/60
0/60
0/60
0/60
16/60
3/60
5/60
5/50
0/50
0/50
0/50
19/50
4/50
0/50
2500
0/50
0/50
5/50
0/50
17/50
5/50
15/50
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in untreated F344 rats, occurred in treated Table7. Treatment-related neoplastic responses: preputial gland, clitoral gland, uterus, and mammary gland.
male and female rats.
Adenomas and carcinomas of the
preputial glands and clitoral glands (female 3,3'-Dimethylbenzidine dihydrochloride
homologue of the preputial glands) oc- Exposure, ppma 0 30 70 150 0 30 70 150
curred frequently in treated rats. Because Preputial gland 2/60 4/45 6/75 9/60 - - - -
preputial gland neoplasms are usually not Clitoral gland - - - - 0/60 14/45 42/75 32/59
overtly aggressive or invasive and rarely Mammarygland 0/60 0/45 0/75 0/60 1/60 1/45 3/75 6/60
metastasize (47,48), classification of these 3,3'-Dimethoxybenzidine dihydrochloride
neoplasms as benign or malignant is diffi- Exposure, ppm 0 80 170 330 0 80 170 330
cult (49). The transplantability ofpreputial Preputial gland 16/60 12/43 33/73 29/59 - - - -
gland neoplasms induced by 3,3'-dimethyl- Clitoral gland - - - - 7/58 27/44 48/74 41/55
benzidine, 3,3'-dimethoxybenzidine and Uterus/cervix - - - - 4/45 2/45 2/60 0/60
Acid Red 114 was investigated to provide Mammarygland 0/60 0/43 o0/3 0/59 1/60 2/45 14/75 20/60
information on the biologic behavior of
these neoplasms (49,50). All neoplasms se- C~l. Acid Red 114 eted for pla nai wereretop s e- Exposure, ppm 0 70 150 300 0 150 300 600 lected for transplantation were retrospec- Prptagln r Preputial gland - - - -- - -- tively diagnosed as carcinomas and Clitoral gland - - - - 11/48 17/32 28/62 23/50
therefore, comparable information was not Mammarygland 0/50 0/35 0/65 0.50 0/50 3/35 6/65 3/50
obtained for preputial gland adenomas.
The transplanted neoplasms did not be- Cl. DirectBlue 15
come anaplastic or less differentiated over Exposure, ppm 0 630 1250 2500 0 630 1250 2500
four serial passages; however, the trans- Preputial gland 8/49 5/35 23/64 9/48 - - - -
plants behaved biologically as malignant Clitoral gland - - - - 7/50 11/35 24/64 29/50
neoplasms in spite of their well differenti- Uterus - - - _ 1/50 0/35 1/65 4/50 -
ated morphology. The latency period was
Not applicable. 'Concentration in drinking water. short and transplants grew rapidly. The re-
sults of these studies confirmed the malig-
nant nature of these preputial gland neoplant s
n ure ofts exposed to the glnd. Table 8. Treatment-related neoplastic responses: intestine, lung, mesotheliomas, brain, and mononuclear cell neoplasms from rats exposed to the benzi- leukemia.
dine congeners and dyes.
In rats treated with 3,3'-dimethylbenzi- Malerats Female rats
dine 3,3'-dimethoxybenzidine, Direct Blue
15, and Acid Red 114, the total numbers 3,3'-Dimethylbenzidinedihydrochloride
ofneoplasms tended to be greater in males Exposure, ppma 0 30 70 150 0 30 70 150
than in females. In addition, tumors of the Small intestine 0/60 0/45 4/75 8/60 0/60 1/45 3/75 5/60
skin, liver, and oral cavity epithelium were Large intestine 0/60 0/45 6/75 15/60 0/60 1/45 3/75 5/60
more common in males than females. Lung 1/60 0/45 8/75 6/60 1/60 1/45 3/74 4/60
Some, but not all, of the four chemicals Mononuclearcelleukemia 0/60 0/45 0/75 0/60 1/60 5/45 6/75 4/60 tested caused marginal increases in Mesotheliomas 0/60 0/45 3/75 4/60 0/60 0/45 0/75 0/60
mononuclear cell leukemia, mesotheliomas,
and tumors of the brain, mammary gland, 3,3'-Dimethoxybenzidine dihydrochloride
lung, or adrenal gland, which may been re- Exposure, ppm 0 80 170 330 0 80 170 330
lated to treatment. Small intestine 0/60 4/45 7/75 5/60 0.60 0/45 0/75 0/60
The numbers of animals with primary Large intestine 0/60 1/45 8/75 8/60 0/60 1/45 1l/75 3/60
malignant neoplasms in the 3,3'-dimethyl- Brain 0/60 2/44 3/5 1/60 0/60 0/45 0/75 O/75
benzidine, 3,3'-dimethoxybenzidine, Acid Mesotheliomas 2/60 1/45 7/75 6/60 0/60 0/45 O/75 O/75
Red 114, and Direct Blue 15 studies are Cl. Acid Red114
shown in Table 9. Malignant tumors were Exposure, ppm 0 70 150 300 0 150 300 600
observed in 83 to 98% ofall high dose ani- Small intestine 0/50 0/35 0/65 0/50- 0/50 0/35 1/65 2/50
mals; 64 to 91% ofmid-dose animals, and Large intestine 0/50 0/35 0/45 0/50 0/50 1/35 0/65 3/50
13 to 80% ofall low-dose animals. Tumor Lung 2/50 2/35 2/65 3/50 1/50 2/35 9/65 4/50
multiplicity was calculated as the number Adrenal medulla 17/50 11/35 27/63 21/49 1/50 3/35 4/64 1/50
of primary malignant tumors per animal. Mononuclearcell leukemia 0/50 0/35 0/65 0/50 12/50 13/35 18/65 5/50
Tumor multiplicity was greater than one
for all dosed animals except those treated CEl.DirectBlue15
wit lo an mi doe of 33-adimethy- Exposure, ppm 0 630 1250 2500 0 630 1250 2500 wihlwan i osso '- ' Small intestine 0/50 1/35 0/65 2/50 0/50 0/35 1/65 3/50 benzidine, and females in the low-dose Large intestine 0/50 1/35 6/65 8/50 0/50 0/35 3/65 1/50 group of Direct Blue 15. In male rats, ma- Brain 0/50 1/35 1/65 2/50 0/50 0/35 0/65 0/50
lignant neoplasms were observed earliest in Mononuclearcell leukemia 17/50 19/35 28/65 20/50 7/50 13/35 27/65 15/50
3,3'-dimethylbenzidine-dosed rats, fol-
lowed by rats dosed with Direct Blue 15, aConcentration in drinking water.
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Table 9. Number of animals with primary malignant neoplasms in all organs.
Control Low Dose Mid Dose High Dose
Males
3,3'-Dimethylbenzidine.2HCla
Animals withmalignant neoplasms
Totalmalignant neoplasms
Tumor multiplicityb
First incidence (days)
3,3'-Dimethoxybenzidine.2HCIC
Animals with malignant neoplasms
Total malignant neoplasms
Tumor multiplicity
First incidence (days)
Acid Red 114d
Animals with malignant neoplasms
Total ,malignant neoplasms
Tumor multiplicity
First incidence, days
Direct Blue 15e
Animals withmmalignant neoplasms
Total malignant neoplasms
Tumor multiplicity
First incidence, days
Females
3,3'-Dimethylbenzidine.2HCla
Animals with malignant neoplasms
Total malignant neoplasms
Tumor multiplicity
First incidence, days
3,3'-Dimethoxybenzidine.2HClC
Animals with malignant neoplasms
Total malignant neoplasms
Tumor multiplicity
First Incidence, days
Acid Red 114d
Animals with malignant neoplasms
Total malignant neoplasms
Tumor multiplicity
First incidence,days
Direct Blue 15e
Animals with malignant
Neoplasms
Total malignant neoplasms
Tumor multiplicity
First incidence (days)
2% (1/60)
1
0.02
419
45% (27/60)
31
0.52
455
66% (33/50)
43
0.86
131
46%(23/50)
25
0.50
445
2% (1/60)
1
0.02
390
45% (27/60)
31
0.52
40
44% (22/50)
26
0.52
431
42% (21/50)
23
0.46
500
13% (6/45)
6
0.13
250
80% (36/45)
59
1.31
266
77% (27/35)
38
1.09
352
77% (27/35)
37
1.06
293
31% (14/45)
18
0.40
357
71% (32/45)
52
1.16
373
71% (25/35)
35
1.0
411
71% (25/35)
29
0.83
463
64% (48/75)
62
0.83
229
88% (66/75)
121
1.61
287
83% (54/65)
78
1.20
325
83% (54/65)
88
1.35
323
65% (49/75)
65
0.87
184
91% (68/75)
96
1.28
220
82% (53/65)
87
1.34
285
86% (56/65)
70
1.08
253
83% (50/60)
80
1.30
209
98% (59/60)
105
1.75
273
86% (43/50)
55
1.10
377
90% (45/50)
83
1.66
243
93% (56/60)
90
1.50
229
93% (56/60)
78
1.30
270
84% (42/50)
51
1.02
229
96% (48/50)
64
1.28
296
a3,3'-Dimethylbenzidine studyterminated after 15 months.bTumor multiplicity calculated as mean number ofmalignant
tumors per animal. c3,3'-Dimethoxybenzidine study terminated after 21 months. dAcid Red 114 studyterminated after
24 months. eDirect Blue 15 studyterminated after22 months.
3,3'-dimethoxybenzidine, and Acid Red
114. In females the order in which tumors
were first detected was: 3,3'-dimethylbenzi-
dine, 3,3'-dimethoxybenzidine, Acid Red
1 14, and Direct Blue 15. The results ofthe
Direct Blue 218 study showed a spectrum
ofneoplastic lesions that was different from
that observed for the other four benzidine
compounds. Incidences ofchemical-related
neoplasms were not as dramatic, and were
observed primarily in the oral cavity epithe-
lium of rats, and in the livers of mice
(Table 10).
Dose-response relationships could not
be established for the carcinogenicity ofthe
benzidine congener dyes and the parent
amines because of the high incidences of
tumors at all doses. These high incidences
of tumors after chronic exposure were un-
expected because higher doses ofthe benzi-
dine congeners and dyes produced little or
no toxicity in prechronic studies. In early
studies of 3,3'-dimethoxybenzidine and
3,3'-dimethylbenzidine, only relatively low
incidences of tumors were observed in
dosed animals (51-54). However, in those
studies, the administration of large, toxic
doses of chemical decreased survival and
may have resulted in a severe underestima-
tion of the carcinogenic potency of these
chemicals.
Quantitative comparisons of the car-
cinogenic potencies ofthe four chemicals is
difficult because of the lack of dose- re-
sponse relationships, as well as differences
in doses and durations oftreatments. Slight
differences in the carcinogenic potencies of
the two benzidine congener dyes are in part
a result ofthe rate at which they are metab-
olized and in part by the carcinogenicity of
the benzidine congener metabolite.
Quantitative differences were observed in
the liver and skin of males and females;
males in all four studies had a higher tumor
incidence at these sites than did females.
However, chemical-induced clitoral gland
tumors of females occurred more com-
monly than preputial gland tumors in
males.
3,3'-Dimethylbenzidine caused a neo-
plastic response at an earlier time than did
3,3'-dimethoxybenzidine, suggesting that
3,3'-dimethylbenzidine may be a more po-
tent carcinogen, possibly because it is ab-
sorbed to a greater extent, or metabolized
to the ultimate carcinogen more efficiently
than 3,3'-dimethoxybenzidine. In addition,
Acid Red 114, the 3,3'-dimethylbenzidine-
derived dye, caused tumors at lower doses
than Direct Blue 15, the 3,3'-dimethoxy-
benzidine derived dye, also suggesting that
3,3'-dimethylbenzidine may be a more po-
tent carcinogen.
Qualitatively, 3,3'-dimethoxybenzidine,
3,3'-dimethylbenzidine, Direct Blue 15,
and Acid Red 114 caused a similar spec-
trum of neoplasms in the Zymbal's gland,
skin, liver, oral cavity, clitoral and preputial
gland, and to a lesser extent in the intestine
of the Fischer F344/N rat. Tumors occur
infrequently at these sites, and the high in-
cidences of tumors at these sites in all four
studies strongly indicates a common mech-
anism.
Two uncommon neoplasms that ap-
peared at relatively high incidences in
treated rats were Zymbal's gland tumors
(males and females) and skin basal cell tu-
mors (males). Most ofthe chemicals tested
by the NTP that induced either Zymbal's
gland or skin tumors in rats also caused tu-
mors in other sites. These tumor inducing
chemicals (e.g., 4-aminobiphenyl, 4,4'-
thiodianiline) all have in common an aro-
matic amine functional group that is
considered to be a "structural alert" for
genotoxic activity, and all are mutagenic in
Salmonella. A number ofaromatic amines,
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or chemicals that are metabolized to aro-
matic amines, cause neoplasms in the
Zymbal's gland ofrats (40). Benzidine, the
parent compound of this series of chemi-
cals, also causes Zymbal's gland tumors in
rats (551 implicating the free amine group
of benzidine as a common site for meta-
bolic activation for this related group of
chemicals. Although, for the most part, the
target sites were similar for the four chemi-
cals, some differences were observed. Acid
Red 114 and its parent congener, 3,3'-di-
methylbenzidine, caused a higher inci-
dence ofliver tumors than did Direct Blue
15 and its parent congener, 3,3'-
dimethoxybenzidine. In addition, signifi-
cantly increased incidences of preputial
gland tumors were seen in male rats treated
with 3,3'-dimethoxybenzidine, 3-,3'-di-
methylbenzidine, and Direct Blue 15, but
not with Acid Red 114. Some, but not all,
ofthe four chemicals tested caused variable
increases in mononuclear cell leukemia,
mesotheliomas, and tumors of the brain,
mammary gland, lung, and adrenal
medulla, which may have been related to
chemical treatment. These slight differ-
ences in sites oftumor origin among stud-
ies are likely a result ofdifferences in dose,
the extent ofabsorption and metabolism of
the different chemicals, and possibly the
effects of impurities in the dyes. Direct
Blue 218, a copper-chelated 3,3'-
dimethoxybenzidine-derived dye, was con-
siderably less carcinogenic than the
benzidine congeners and nonchelated dyes;
it was also nonmutagenic.
Chelation with copper of the hydroxy
groups of the benzidine congener is be-
lieved to prevent metabolism ofthe dye to
the ultimate carcinogen. The relatively low
carcinogenic response to Direct Blue 218
supports the concept that copper chelation
inhibited metabolic activation ofthe dye to
a large extent; however, the presence oforal
cavity tumors in rats and liver neoplasms in
mice suggests that copper chelation does
not completely eliminate the carcinogenic
effects ofthe dye. These neoplasms may be
a result ofincomplete inhibition ofmetab-
olism ofthe chelated dye, and possibly a re-
sult of carcinogenic impurities in the dye.
The Direct Blue 218 used in these studies
was only 60% pure. In addition to organic
impurities, the dye also contained free cop-
per which may also be toxic. It is also pos-
sible that the oral cavity tumors were a
direct effect ofthe chemical in dosed feed.
The different target sites of Direct Blue
218 in rats and mice suggests potential
species differences in metabolism of this
dye. Further support for species differences
in metabolism of benzidine compounds is
provided by studies of3,3'-dimethoxybenzi-
dine and 3,3'- dimethylbenzidine adminis-
tered in drinking water to BALB/c mice.
Although these compounds are potent, mul-
tisite carcinogens in rats, 3,3'-dimethoxy-
benzidine had no apparent carcinogenic
effect (37),and 3,3'-dimethylbenzidine
caused only a low incidence oflung tumors
in treated mice (38). Metabolic differences
may also exist between mouse strains, since
liver neoplasms were observed in B6C3F1
mice and lung tumors were observed in
BALB/c mice.
OncogeneActivation
DNA from neoplasms of skin, preputial
and clitoral gland, mammary gland, and
intestines of rats exposed to 3,3'-
dimethoxybenzidine, 3,3'-dimethylbenzi-
dine, Direct Blue 15, orAcid Red 114, was
analyzed for dominant transforming genes
using the NIH 3T3 plate transfection assay
(56). Oncogenes detectable by DNA
transfection analysis were present in 35 of
59 skin, clitoral gland or preputial gland
neoplasms that had been induced in F344
rats by the benzidine congeners or derived
dyes. DNA from both benign and malig-
nant neoplasms was capable of inducing
morphologically transformed foci in NIH
3T3 fibroblasts.
A high percentage of the induced rat
neoplasms contained activated alleles of ei-
ther H- or N-ras. Those neoplasms with
activated H-ras contained point mutations
in codon 12, 13, or 61. Point mutations at
codon 61 accounted for approximately
50% of the H-ras gene activations in both
3,3'-dimethylbenzidine and 3,3'-dimeth-
oxybenzidine induced tumors, with C->A
transversions (or GC-T transversions in the
antisense strand) being the predominant
mutation at codon 61 in both groups. The
mutations detected at codon 12 were exclu-
sively G-÷A transitions whereas the muta-
tions at codon 13 were predominantly
G-*C transversions.
The detection of a high percentage of
activated oncogenes in these chemical-in-
duced neoplasms is in sharp contrast to the
relatively low frequency of activated onco-
genes found in spontaneously occurring
neoplasms of F344 rats (57). These obser-
vations suggest that activation of cellular
ras genes by point mutation may be an im-
portant step in induction oftumors in rats
treated with the benzidine congeners and
derived dyes.
A number ofepidemiologic studies sup-
port the causal relationship between expo-
sure to benzidine and the occurrence of
bladder cancer in humans (1). The finding
that H-ras gene activation occurs in a por-
tion ofhuman bladder tumors (58,59) and
the above results suggesting that ras gene
activation is an important step in the in-
duction of tumors in rats treated with the
benzidine congeners and derived dyes, sug-
gests that ras activation can be involved in
one pathway of human urothelial cell
transformation.
Summary
Consumption ofdrinking water containing
the benzidine congeners 3,3'-dimethylben-
zidine and 3,3'-dimethoxybenzidine, and
the prototypical benzidine congener dyes,
Acid Red 114 and Direct Blue 15 led to a
similar spectrum of neoplasms. The high
incidences oftumors at the same sites in all
four studies strongly indicates a common
mechanism. The detection of a high per-
centage of activated oncogenes in these
chemical-induced neoplasms suggests that
activation of cellular ras genes by point
mutation may be an important step in in-
duction oftumors in rats treated with ben-
zidine congeners and derived dyes.
Direct Blue 218, a metallized 3,3'-
dimethoxybenzidine-derived dye, was con-
siderably less carcinogenic than the
benzidine congeners and nonchelated dyes
and was also nonmutagenic. However, the
presence of oral cavity tumors in rats and
liver neoplasms in mice suggests that cop-
per chelation does not completely eliminate
the carcinogenic effects ofmetallized dyes.
Conclusions
The broad objective ofthe benzidine initia-
tive was to generate a body ofscientific in-
formation that would facilitate regulatory
decision making regarding the toxicologic
and carcinogenic risk associated with expo-
sure to benzidine and benzidine congener
derived dye materials. The carcinogenicity
studies provided clear evidence that the
benzidine congeners and prototypical dyes
derived from these parent amines are po-
tent carcinogens in animals. Based upon
the results ofmetabolism and mutagenicity
studies of other benzidine- and benzidine-
congener-derived dyes, one would predict
that most, if not all, dyes based on these
chemicals are carcinogens.
The metabolism, disposition, muta-
genicity, and carcinogenicity data from
these studies provide sufficient evidence
that the benzidine and benzidine-congener-
derived dyes should be regulated as proba-
ble human carcinogens.
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